Skip to content

Combined detection of serum circ7991 and other markers for early diagnosis of gastric cancer and its mechanism of action.

Combined detection of serum circ7991 and other markers for early diagnosis of gastric cancer and its mechanism of action.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106956
Enrollment
Unknown
Registered
2025-07-31
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Index test:In this study, real-time quantitative PCR will be used to detect the expression levels of gastric cancer tumor markers circRNAs, eccDNAs, etc. The instruments used include NanoDrop™ One, Qu

Sponsors

Drum Tower Hospital Affiliated to Nanjing University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Eligible gastric cancer patients must meet all of the following criteria: (1) Histopathologically confirmed diagnosis of gastric cancer (2) No prior anticancer treatment before surgery (including chemotherapy, radiotherapy, immunotherapy, or targeted therapy) (3) Complete clinical and pathological data available (4) No history of gastric cancer or prior related treatment Eligible gastritis patients must meet all of the following criteria: (1) Diagnosis of chronic gastritis confirmed by endoscopy (e.g., chronic superficial gastritis, chronic atrophic gastritis) (2) No prior history of malignancy (3) Complete clinical data available Eligible healthy controls must meet all of the following criteria: (1) No evidence of disease confirmed by physical examination (2) No prior history of malignancy (3) Complete clinical data available

Exclusion criteria

Exclusion criteria: (1) Preoperative chemotherapy or immunotherapy or targeted therapy. (2) Lack of clinical information. (3) Suffering from other malignant tumors in the past.

Design outcomes

Primary

MeasureTime frame
circRNAs and eccDNAs;Accuracy;Sensitivity;Specificity;

Countries

China

Contacts

Public ContactYu Zhang

Drum Tower Hospital Affiliated to Nanjing University School of Medicine

zhangyu001100@sina.com+86 188 5140 0030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026